General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 331: What is a Type E adverse drug reaction?

A. Toxicity
B. Augmented pharmacologic effect
C. Teratogenesis
D. Withdrawal reaction (Correct Answer)

Explanation: **Explanation:** Adverse Drug Reactions (ADRs) are most commonly classified using the **Rawlins and Thompson classification**, which categorizes reactions from Type A to Type F based on their mechanism and timing. **Why Option D is Correct:** **Type E (End-of-use)** reactions occur when a drug is suddenly discontinued. These are **withdrawal reactions** [1]. The body, having adapted to the presence of the drug (physiological dependence), reacts to its absence [1]. Classic examples include: * **Beta-blockers:** Rebound hypertension or tachycardia. * **Opioids/Benzodiazepines:** Withdrawal syndrome (insomnia, anxiety, tremors). * **Clonidine:** Rebound hypertensive crisis. **Why the Other Options are Incorrect:** * **Option A (Toxicity):** This is a **Type A (Augmented)** reaction. It is dose-dependent and a predictable extension of the drug’s primary pharmacology (e.g., bleeding with Heparin) [2], [4]. * **Option B (Augmented pharmacologic effect):** This is the definition of **Type A** reactions [4]. They are common, predictable, and usually managed by dose adjustment [4]. * **Option C (Teratogenesis):** This falls under **Type D (Delayed)** reactions. These occur long after the drug exposure, including carcinogenesis and teratogenicity (e.g., Phocomelia with Thalidomide) [3]. **NEET-PG High-Yield Pearls:** * **Type A (Augmented):** Dose-related, predictable (e.g., Hypoglycemia with Insulin) [2]. * **Type B (Bizarre):** Non-dose related, unpredictable, idiosyncratic (e.g., Anaphylaxis with Penicillin). * **Type C (Chronic):** Occurs with long-term use (e.g., Analgesic nephropathy). * **Type D (Delayed):** Carcinogenicity/Teratogenicity [3]. * **Type E (End-of-use):** Withdrawal [1]. * **Type F (Failure):** Unexpected failure of therapy (e.g., Drug interactions reducing oral contraceptive efficacy).

Question 332: H1 antagonist has all the functions except?

A. Anti-pruritic
B. Sedation
C. Decreased gastric acid secretion (Correct Answer)
D. Antiemetic

Explanation: **Explanation:** The question tests the distinction between Histamine receptor subtypes and their physiological roles. Histamine acts via four primary receptors ($H_1$ to $H_4$), each coupled to different signaling pathways and located in distinct tissues. **Why Option C is Correct:** Gastric acid secretion is mediated exclusively by **$H_2$ receptors** located on the parietal cells of the stomach. Activation of $H_2$ receptors increases cAMP, leading to acid production. Therefore, $H_1$ antagonists have no effect on gastric acid; this function requires $H_2$ blockers like Ranitidine or Famotidine. **Analysis of Incorrect Options:** * **A. Anti-pruritic:** $H_1$ receptors are located on peripheral nerve endings. Blocking them inhibits the "itch" sensation, making $H_1$ blockers the mainstay for treating urticaria and allergic dermatitis. * **B. Sedation:** First-generation $H_1$ antihistamines (e.g., Diphenhydramine, Promethazine) are highly lipophilic and cross the blood-brain barrier. They block central $H_1$ receptors involved in wakefulness, leading to sedation. * **C. Antiemetic:** Certain $H_1$ blockers (especially Promethazine and Doxylamine) have significant anticholinergic activity and act on the vestibular apparatus and the chemoreceptor trigger zone (CTZ), making them effective for motion sickness and morning sickness. **NEET-PG High-Yield Pearls:** * **Second-generation $H_1$ blockers** (e.g., Cetirizine, Loratadine, Fexofenadine) are non-sedating because they have poor CNS penetration. * **Terfenadine and Astemizole** (older 2nd gen) were withdrawn due to **QT interval prolongation** (Torsades de pointes) when co-administered with CYP3A4 inhibitors (e.g., Erythromycin, Ketoconazole). * **Fexofenadine** is the active metabolite of Terfenadine and is safe (no cardiotoxicity).

Question 333: All of the following are true about atracurium, EXCEPT:

A. Should be avoided in asthmatic patients.
B. Metabolism is by Hofmann degradation.
C. Laudanosine toxicity is present.
D. Histamine release is rare. (Correct Answer)

Explanation: **Atracurium** is a benzylisoquinolinium neuromuscular blocking agent (NMBA) frequently tested in NEET-PG due to its unique metabolic pathway and side-effect profile. ### **Explanation of the Correct Answer** **Option D is the correct answer (the false statement)** because **histamine release is common** with atracurium, not rare. Atracurium belongs to the benzylisoquinolinium class, which is notorious for triggering non-immunological mast cell degranulation. This leads to clinical manifestations such as flushing, hypotension, and bronchospasm. ### **Analysis of Incorrect Options** * **Option A (Avoid in asthma):** Since atracurium causes significant histamine release, it can trigger bronchoconstriction. Therefore, it is generally avoided in patients with hyperreactive airways or bronchial asthma. * **Option B (Hofmann degradation):** This is a hallmark feature. Atracurium undergoes spontaneous non-enzymatic degradation at physiological pH and temperature. This makes it the drug of choice in patients with **liver or kidney failure**. * **Option C (Laudanosine toxicity):** Laudanosine is the major metabolite of atracurium. It is a CNS stimulant that can cross the blood-brain barrier and may lower the seizure threshold, potentially causing convulsions in high doses or prolonged infusions. ### **High-Yield Clinical Pearls for NEET-PG** * **Cisatracurium:** An isomer of atracurium that is more potent, undergoes Hofmann degradation, but importantly **does not cause histamine release**. * **Organ-Independent Elimination:** Both atracurium and cisatracurium are preferred in "multi-organ failure" because they do not rely on renal or hepatic clearance. * **Temperature/pH Sensitivity:** Since Hofmann degradation is temperature-dependent, the duration of action of atracurium is prolonged in patients with **hypothermia** or **acidosis**.

Question 334: 5HT3 receptors belong to which of the following group of receptors?

A. Metabotropic
B. Fastest acting receptors (Correct Answer)
C. Slowest acting receptors
D. Enzymatic receptors

Explanation: **Explanation:** The correct answer is **B. Fastest acting receptors.** **Mechanism and Classification:** 5HT3 receptors are unique among serotonin receptors. While all other serotonin receptors (5HT1, 2, 4, 5, 6, 7) are G-protein coupled receptors (GPCRs), the **5HT3 receptor is a ligand-gated ion channel (ionotropic receptor).** Ionotropic receptors allow the direct flow of ions (sodium and potassium) across the cell membrane upon ligand binding, leading to rapid depolarization. This process occurs within milliseconds, making them the **fastest-acting** class of receptors in the body. **Analysis of Options:** * **A. Metabotropic:** These are GPCRs that act via second messengers (like cAMP or IP3/DAG). Their response takes seconds to minutes. All other 5HT receptors are metabotropic, but 5HT3 is not. * **C. Slowest acting receptors:** Nuclear receptors (which regulate gene transcription) are the slowest, taking hours to days. * **D. Enzymatic receptors:** These are transmembrane proteins with intrinsic enzymatic activity (e.g., Tyrosine Kinase receptors like the Insulin receptor). They are slower than ionotropic receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Location:** 5HT3 receptors are predominantly found in the **Chemoreceptor Trigger Zone (CTZ)** and the gastrointestinal tract (vagal afferents). * **Clinical Use:** 5HT3 antagonists (e.g., **Ondansetron, Palonosetron**) are the drugs of choice for **Chemotherapy-Induced Nausea and Vomiting (CINV)** and post-operative vomiting. * **Other Ionotropic Receptors:** Remember the mnemonic "N-G-A-5" for major ionotropic receptors: **N**icotinic (ACh), **G**ABA-A, **A**MPA/NMDA (Glutamate), and **5**HT3.

Question 335: Which mitochondrial enzyme is involved in the metabolism of clopidogrel and proton pump inhibitors?

A. CYP 2A
B. CYP 2B
C. CYP 2C19 (Correct Answer)
D. CYP 2D6

Explanation: **Explanation:** **CYP 2C19** is the correct answer because it is the primary hepatic microsomal enzyme responsible for the metabolism of both Clopidogrel and most Proton Pump Inhibitors (PPIs), such as Omeprazole and Esomeprazole. 1. **Clopidogrel Metabolism:** Clopidogrel is a **prodrug**. It requires a two-step activation process in the liver to become its active thiol metabolite. CYP 2C19 is the most critical enzyme in this conversion. Patients who are "poor metabolizers" due to genetic polymorphisms in the *CYP2C19* gene have reduced antiplatelet efficacy and a higher risk of cardiovascular events. 2. **PPI Interaction:** PPIs are also metabolized by CYP 2C19. This leads to a significant **drug-drug interaction**: PPIs (especially Omeprazole) can inhibit CYP 2C19, thereby preventing the activation of Clopidogrel and reducing its clinical efficacy. **Analysis of Incorrect Options:** * **CYP 2A:** Primarily involved in the metabolism of nicotine and some toxins; it plays no significant role in Clopidogrel activation. * **CYP 2B (specifically 2B6):** Involved in the metabolism of drugs like Bupropion and Cyclophosphamide. * **CYP 2D6:** A highly polymorphic enzyme responsible for metabolizing ~25% of clinical drugs, including beta-blockers, antidepressants, and the activation of Codeine to Morphine. It is not the primary enzyme for Clopidogrel. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** If a patient on Clopidogrel requires a PPI, **Pantoprazole** or **Rabeprazole** are preferred because they have the least inhibitory effect on CYP 2C19. * **Genetic Polymorphism:** *CYP2C19*2* is the most common loss-of-function allele associated with "clopidogrel resistance." * **Mitochondrial vs. Microsomal:** Note that while the question mentions "mitochondrial," these CYP enzymes are technically **microsomal** (located in the Smooth Endoplasmic Reticulum). In the context of NEET-PG, focus on the specific enzyme isoform.

Question 336: Which of the following is a prodrug?

A. Enalapril (Correct Answer)
B. Clonidine
C. Salmeterol
D. Acetazolamide

Explanation: A **prodrug** is a pharmacologically inactive compound that must undergo metabolic conversion (usually in the liver) to become an active metabolite [1, 2]. **Correct Option: A. Enalapril** Enalapril is a classic example of a prodrug. It is an ester that is hydrolyzed by hepatic esterases into its active form, **Enalaprilat** [2]. Most ACE inhibitors are prodrugs (e.g., Ramipril, Perindopril) because the active forms have poor oral bioavailability [3]. * **Exception:** **Lisinopril and Captopril** are NOT prodrugs; they are active as administered [3]. **Incorrect Options:** * **B. Clonidine:** An alpha-2 adrenergic agonist used in hypertension. It is active in its parent form and does not require metabolic activation. * **C. Salmeterol:** A long-acting beta-2 agonist (LABA) used in asthma. It acts directly on the receptors upon inhalation. * **D. Acetazolamide:** A carbonic anhydrase inhibitor used in glaucoma and altitude sickness. It is an active drug excreted largely unchanged by the kidneys. **High-Yield Clinical Pearls for NEET-PG:** * **Active Metabolite of Enalapril:** Enalaprilat (available only intravenously for hypertensive emergencies). * **Common Prodrugs Mnemonic (All Prefer Dogs):** **A**CE inhibitors (except Lisinopril/Captopril), **P**roton Pump Inhibitors (Omeprazole), **D**opamine precursors (Levodopa). * **Other High-Yield Prodrugs:** Cyclophosphamide (activated by CYP450), Clopidogrel, Tamoxifen, Fluorouracil, and Terfenadine. * **Advantage:** Prodrugs are often designed to improve oral absorption or decrease gastrointestinal irritation.

Question 337: Magnesium is used in the treatment of which of the following conditions?

A. Diarrhea
B. Tetany (Correct Answer)
C. Intractable seizures
D. Cardiac arrest

Explanation: **Explanation:** **Magnesium** acts as a physiological calcium channel blocker and plays a crucial role in neuromuscular stability. **1. Why Tetany is Correct:** Tetany is characterized by increased neuromuscular excitability. While most commonly associated with hypocalcemia, it can also be caused by **hypomagnesemia**. Magnesium is essential for the release of Parathyroid Hormone (PTH) and the responsiveness of end-organs to PTH. In cases of "refractory tetany" (where calcium levels are normal or calcium replacement fails), magnesium deficiency is the likely culprit. Administering Magnesium Sulfate ($MgSO_4$) restores ionic balance and stabilizes the neuronal membrane, effectively treating the tetany. **2. Why Other Options are Incorrect:** * **Diarrhea:** Magnesium salts (like Magnesium Citrate or Hydroxide) are **osmotic laxatives**. They cause diarrhea as a side effect or are used to treat constipation, not to treat diarrhea. * **Intractable Seizures:** While $MgSO_4$ is the drug of choice for **Eclamptic seizures**, it is not a first-line or standard treatment for general intractable seizures (Status Epilepticus), where Benzodiazepines, Phenytoin, or Levetiracetam are preferred. * **Cardiac Arrest:** Magnesium is not used in routine cardiac arrest. It is specifically indicated only if the arrest is caused by **Torsades de Pointes** (polymorphic ventricular tachycardia) or suspected hypomagnesemia. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** $MgSO_4$ is the DOC for **Eclampsia** (prophylaxis and treatment) and **Torsades de Pointes**. * **Therapeutic Monitoring:** When administering $MgSO_4$, always monitor the **Patellar reflex** (first sign of toxicity is loss of reflex), respiratory rate, and urine output. * **Antidote:** The specific antidote for Magnesium toxicity is **Calcium Gluconate**.

Question 338: The maximum tolerated dose of a new drug is evaluated in which phase of clinical trials?

A. Phase 1 (Correct Answer)
B. Phase 2
C. Phase 3
D. Phase 4

Explanation: **Explanation:** The primary objective of **Phase 1 Clinical Trials** is to establish the safety and tolerability of a new drug. This is achieved by determining the **Maximum Tolerated Dose (MTD)**—the highest dose of a drug that can be administered without causing unacceptable side effects. * **Why Phase 1 is correct:** It is the first stage of testing in humans (usually 20–80 healthy volunteers, except for toxic drugs like anti-cancer agents). Researchers use a "dose-escalation" design to identify the MTD and the Dose-Limiting Toxicity (DLT). It also evaluates the drug's pharmacokinetics (ADME) and pharmacodynamics. **Analysis of Incorrect Options:** * **Phase 2:** Focuses on **Efficacy** ("Does it work?") and finding the optimal therapeutic dose range in a small group of patients (100–300) with the target disease. * **Phase 3:** Focuses on **Confirmation** of efficacy and safety in a large patient population (1,000–3,000). It compares the new drug against the current "Gold Standard" (Standard of Care) or a placebo. * **Phase 4:** Also known as **Post-Marketing Surveillance**. It occurs after the drug is approved to detect rare or long-term adverse effects in the general population. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Also called **Microdosing** studies; used to determine human PK parameters using sub-therapeutic doses. * **Phase 1:** Safety, Tolerability, MTD, and PK. * **Phase 2:** Therapeutic Exploration and Efficacy. * **Phase 3:** Therapeutic Confirmation and Comparative studies. * **Phase 4:** Post-marketing surveillance; identifies **Rare Adverse Effects** (e.g., Phocomelia with Thalidomide).

Question 339: Which of the following is true regarding drugs that are highly bound to albumin?

A. They effectively cross the blood-brain barrier.
B. They have a large volume of distribution.
C. They are easily filtered at the glomerulus.
D. They can undergo competition with other drugs for albumin binding sites. (Correct Answer)

Explanation: **Explanation:** The correct answer is **D**. Plasma protein binding (primarily to albumin) significantly influences a drug's pharmacokinetics. Only the **unbound (free) fraction** of a drug is pharmacologically active, capable of crossing membranes, and available for metabolism or excretion. 1. **Why D is correct:** Albumin has a finite number of binding sites. When two drugs with high affinity for albumin (e.g., Warfarin and Sulfonamides) are administered together, they compete for these sites. This can lead to **displacement interactions**, where one drug displaces another, suddenly increasing the free, active concentration of the displaced drug, potentially leading to toxicity. 2. **Why the other options are incorrect:** * **Option A:** Drugs bound to albumin form a large complex that cannot cross the tight junctions of the **blood-brain barrier**. Only free drugs can enter the CNS. * **Option B:** High protein binding keeps the drug sequestered within the vascular compartment. This results in a **low Volume of Distribution (Vd)**, as the drug does not easily distribute into peripheral tissues. * **Option C:** The glomerular basement membrane prevents the filtration of large proteins like albumin. Therefore, drugs bound to albumin are **not filtered** at the glomerulus; only the free fraction undergoes filtration. **High-Yield Clinical Pearls for NEET-PG:** * **Albumin** primarily binds **acidic drugs** (e.g., NSAIDs, Warfarin, Phenytoin). * **Alpha-1 acid glycoprotein (AAG)** primarily binds **basic drugs** (e.g., Lidocaine, Propranolol, Tricyclic antidepressants). * **Hypoalbuminemia** (seen in liver disease or nephrotic syndrome) increases the free fraction of highly bound drugs, necessitating dose adjustments to avoid toxicity.

Question 340: What phase of clinical trials involves randomized controlled multicenter trials for a drug?

A. Phase I
B. Phase 2
C. Phase 3 (Correct Answer)
D. Phase 4

Explanation: **Explanation:** **Phase 3** clinical trials are designed to confirm the efficacy and safety of a new drug in a large, diverse patient population (typically 1,000–3,000 patients). These are **Randomized Controlled Multicenter Trials (RCTs)** that compare the new drug against the current "Gold Standard" treatment or a placebo. This phase is critical for establishing the risk-benefit ratio and providing the definitive data required for New Drug Application (NDA) submission and marketing approval. **Why other options are incorrect:** * **Phase 1:** Focuses on **safety and tolerability** in a small group (20–80) of healthy volunteers (except for toxic drugs like anti-cancer agents). It is not multicenter or focused on efficacy. * **Phase 2:** Known as the **"Proof of Concept"** phase. It involves a smaller group of patients (100–300) to determine the therapeutic dose range and initial efficacy. While it can be randomized, it is rarely a large-scale multicenter trial. * **Phase 4:** This is **Post-Marketing Surveillance**. It occurs after the drug is launched to detect rare long-term adverse effects (e.g., Phocomelia with Thalidomide) and is not a controlled trial. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Human Microdosing studies (sub-therapeutic doses) used to study pharmacokinetics. * **Phase 1:** Maximum Tolerated Dose (MTD) is determined here. * **Phase 2:** Highest rate of drug failure occurs in this phase. * **Phase 3:** Often referred to as "Pivotal Trials." * **Phase 4:** Helps in identifying "Low-frequency" adverse drug reactions (ADRs).

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free